4203-18-3

Basic information

• Product Name: 4,6-DICHLOROQUINOLINE
• Synonyms: 4,6-DICHLOROQUINOLINE;4-CHLORO-6-CHLOROQUINOLINE;4,6-Dichloroquinoline 98%;Ux00000916;4,6-dichloroquinoline(SALTDATA: FREE);6-dichloroquinoline;4,6-Dichloroquinoline98%
• CAS NO: 4203-18-3
• Molecular Formula: C₉H₅Cl₂N
• Molecular Weight: 198.05
• EINECS: -0
• Product Categories: blocks;Heterocycles;Quinolines;Quinoline&Isoquinoline
• Mol File: 4203-18-3.mol
• Article Data: 11

Chemical Properties

• Melting Point: 104-105℃
• Boiling Point: 281.961 °C at 760 mmHg
• Flash Point: 151.325 °C
• Appearance: /
• Density: 1.407
• Vapor Pressure: 0.00589mmHg at 25°C
• Refractive Index: 1.66
• PKA: 2.76±0.16(Predicted)
• CAS DataBase Reference: 4,6-DICHLOROQUINOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4,6-DICHLOROQUINOLINE(4203-18-3)
• EPA Substance Registry System: 4,6-DICHLOROQUINOLINE(4203-18-3)

Safety Data

• Hazard Codes: Xi,T
• Statements: 25-41
• Safety Statements: 26-39-45
• RIDADR: UN 2811 6.1 / PGIII
• WGK Germany: 3
• Hazardous Substances Data: 4203-18-3(Hazardous Substances Data)

Usage

Uses

4,6-dichloroquinoline is a useful research chemical.

Chemical Properties

Yellow solid

Synthesis Reference(s)

Journal of the American Chemical Society, 68, p. 1264, 1946 DOI: 10.1021/ja01211a038

InChI:InChI=1/C9H5Cl2N/c10-6-1-2-9-7(5-6)8(11)3-4-12-9/h1-5H

Upstream product

• 70271-77-1 6-chloro-4-hydroxyquinoline-3-carboxylic acid ethyl ester 
• 79607-22-0 6-chloro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid ethyl ester 
• 53977-19-8 6-chloro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid 
• 35973-14-9 6-chloro-4-hydroxy-3-quinoline carboxylic acid 
• 25063-46-1 5-(((4-chlorophenyl)amino)methylene)-2,2-dimethyl-1,3-dioxane-4,6-dione 
• 23432-43-1 6-chloro-4-hydroxyquinoline 
• 6563-10-6 6-chloroquinoline N-oxide 
• 21921-70-0 6-chloroquinolin-4(1H)-one 
• 612-57-7 6-chloroquinoline 
• 106-47-8 4-chloro-aniline 
• 19056-79-2 diethyl 4-chloroanilinomethylenemalonate 

Downstream Products

• 133325-73-2 6-chloro-4-p-tolylmercapto-quinoline 
• 857439-65-7 N-(6-chloro-[4]quinolyl)-o-phenylenediamine 
• 20028-60-8 6-Chlor-4-amino-chinolin 
• 676262-10-5 6-chloro-4-methoxyquinoline 
• 103914-57-4 4,6-dichloro-2-(4-fluorophenyl)quinoline 
• 75-18-3 dimethylsulfide 
• 1219100-98-7 4,6-di-(methylsulfanyl)quinoline 
• 41037-29-0 6-chloro-4-methylquinoline 

Relevant articles and documents

A Selective and Orally Bioavailable Quinoline-6-Carbonitrile-Based Inhibitor of CDK8/19 Mediator Kinase with Tumor-Enriched Pharmacokinetics

Senexins are potent and selective quinazoline inhibitors of CDK8/19 Mediator kinases. To improve their potency and metabolic stability, quinoline-based derivatives were designed through a structure-guided strategy based on the simulated drug–target dockin

QUINOLINE-BASED COMPOUNDS AND METHODS OF INHIBITING CDK8/19

Disclosed herein are quinoline-based compounds and method for inhibiting CDK8 or CDK19 for the intervention in diseases, disorders, and conditions. The quinoline-based composition comprise substituents at quinoline ring positions 4 and 6, wherein the substituent at position 4 is selected from a substituted or unsubstituted arylalkylamine or a substituted or unsubstituted arylhetrocyclylamine. Pharmaceutical compositions comprising the substituted qunioline compositions, methods of inhibiting CDK8 or CDK19, and methods of treating CDK8/19-associated diseases, disorders, or conditions are also disclosed.

Synthesis, molecular docking study, and evaluation of the antiproliferative action of a new group of propargylthio- and propargylselenoquinolines

This study describes the synthesis of a new group of halogenopropargylthio- , dipropargylthio-, and halogenopropargylseleno-quinoline derivatives. The ability of all of the synthesized compounds to inhibit the proliferation of the T-47D, MCF-7, MDA-MB-231, and SNB-19 cell lines was determined with the WST-1 assay. The normal fibroblast cell line (HFF-1) was used as a control. The cytotoxic properties of these new, modified propargylquinoline derivatives were comparable to those of cisplatin. The most active compounds, 4,7-dipropargylthiquinoline (8b) and 7-chloro-4-propargylselenoquinoline (5b), were docked into the binding site of human CYP1A1 and CYP1B1. Our data indicate that these derivatives may present promising chemotherapeutic agents, possibly targeting CYP1s pathway.